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ceft Ventricular Systolic
ysfunction in Rheumatoid Disease
hatia et al. (1) report an increased prevalence of left ventricular
LV) systolic dysfunction among patients with rheumatoid disease
n comparison to the general population based on a visual estimate
f echocardiographic LV ejection fraction. The investigators
cknowledge that this observation may be due to significantly higher
revalences of hypertension, diabetes mellitus, and smoking
mong the rheumatoid-disease patients, but they do not provide
nalyses adjusting for these important confounders. Thus, al-
hough ischemic heart disease (and preclinical atherosclerosis)
ccur prematurely in patients with rheumatoid disease, the present
tudy does not distinguish between traditional cardiovascular
isease risk factors as opposed to rheumatoid disease-related
actors being primarily responsible for their observation. Preva-
ences of previous myocardial infarction are comparable in the
atients and general population, and previous myocardial infarc-
ion is strongly related to LV systolic dysfunction among patients
ith rheumatoid disease. Thus the higher prevalence of LV
ystolic dysfunction among patients with rheumatoid disease is
omewhat difficult to reconcile with these two observations.
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EPLY
e thank Dr. Roman for her interest in our study (1). Reported
yocardial infarction (MI) was an independent predictor of left
entricular systolic dysfunction (LVSD) in both the rheumatoid
nd general populations, but the prevalence of LVSD was still
igher in the rheumatoid population despite the prevalence of
eported MI being not significantly different between the 2
opulations (1). This may still relate to ischemic heart disease
IHD), which is more prevalent among rheumatoid patients (2).
ndeed, IHD may be less clinically apparent among rheumatoid
atients, partly because of their limited exercise tolerance due to
rthritis and also misinterpretation of the cause of chest pain. For
xample, rheumatoid patients are more likely to experience unrec-
gnized MI than nonrheumatoid control subjects (3). Further-
ore, cardiac ischemia (identified by thallium scintigraphy) was
ore frequent (and more often clinically silent) in rheumatoid satients compared to counterparts with osteoarthritis (4). In our
ohort (1), ischemic heart disease was the likely underlying cause of
VSD in subjects who had denied prior cardiac disease or cardiac
ymptoms.
Although diagnosed hypertension was more prevalent in the
ohort with rheumatoid disease, this may partly reflect the fact that
heir blood pressures were probably measured more frequently than
he general population cohort, and thus they were more likely to
ave been detected. Given that we found definite LVSD in only
.0% of treated hypertensive subjects in another arm of the
CHOES (Echocardiographic Heart of England Screening) study
5), hypertension seems unlikely to explain most of the excess
revalence of LVSD in the rheumatoid population.
Finally, although the exact mechanism of the high prevalence of
VSD in subjects with rheumatoid disease is still uncertain, this
oes not detract from the main conclusion of our study (1), namely
hat clinicians should be aware of the association and consider
chocardiographic screening for those at risk.
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nprotected Left Main Disease:
tent or Surgery?
n a recent issue of the Journal, Price et al. (1) reported the clinical
nd angiographic follow-up of 50 consecutive patients undergoing
irolimus-eluting stent implantation for unprotected left main
oronary-artery (ULMCA) stenosis. This carefully performed
tudy (i.e., 98% of angiographic follow-up) shows a surprisingly
